The Autopsy / Case File · Overdose & Substance
The Overdoses That Didn't Happen
A single document — a standing order, signed once by a state health official instead of once per patient by a doctor — is the legal mechanism that lets a pharmacist hand naloxone across the counter to anyone who asks. Where it exists and where pharmacies actually use it, opioid deaths measurably diverge from the towns next door. Where it doesn't, or where dispensing lags, that divergence is exactly what a death certificate can't show: the overdose that had no reversal drug within reach.
CDC data on retail pharmacy naloxone dispensing found a 106 percent single-year jump from 2017 to 2018, driven substantially by standing-order laws spreading state by state — yet even at that peak, the national rate came to only one naloxone prescription dispensed for every 69 high-dose opioid prescriptions, with a 25-fold gap between the best- and worst-served counties, concentrated in rural America. A 2024 JAMA Network Open study tracking all 351 Massachusetts municipalities across six years found something more specific: towns where pharmacies used the state's standing order saw opioid fatality rates decline by a further 16 percent a year, relative to towns that never adopted it — but the effect took time to appear, showing no measurable change in the first quarter and only building, year over year, as the option became familiar enough to actually be used.
Join the discussion →
Naloxone itself is not the hard part. It is a decades-old opioid antagonist, cheap to manufacture, safe enough that giving it to someone who turns out not to be overdosing does no meaningful harm, and effective enough that a bystander with no medical training can reverse a fentanyl overdose in progress with a single nasal spray. The hard part, for most of naloxone's history, was getting it into that bystander's hands before the overdose happened rather than after. A prescription drug legally required a prescription — written for a named patient, by a doctor who had seen that patient, for that patient's own use — which meant the people best positioned to save a life during an overdose (a using partner, a parent, a roommate, a stranger who happened to be nearby) usually had no legal way to be holding the drug in the first place. The standing order is the fix states built for that specific bottleneck, and it is worth being precise about what it actually is: not a change to what naloxone does, but a change to who is allowed to hand it over, and to how many transactions one doctor's signature can cover.
One Signature, Every Pharmacy in the State
A standing order works by inverting the normal prescribing relationship. Instead of a doctor writing an individual prescription for an individual patient, a single authorized prescriber — typically a state's chief medical officer or health commissioner — issues one blanket order that functions as a prescription for anyone who walks into a participating pharmacy and asks for naloxone, without that person's name ever being attached to an individual doctor's visit. Arizona's statewide standing order took effect August 6, 2016. Massachusetts made the order mandatory for its pharmacies by the end of 2017, after three years in which adoption was voluntary. By June 2019, 29 states had some form of statewide standing order in place; by January 2023, according to the Network for Public Health Law's 50-state survey, that had grown to 33 jurisdictions with a single order covering every pharmacy statewide, out of all 50 states plus Washington, D.C. that by then had adopted naloxone access laws of some kind — whether a statewide standing order, a pharmacist prescriptive authority provision, or a collaborative practice agreement model. The legal architecture, in other words, is now close to universal on paper. What varies enormously — and what turns out to matter more than the law's mere existence — is whether pharmacies actually use it.
A Number That Sounds Better Than the Gap Underneath It
CDC's 2019 Vital Signs report on pharmacy-based naloxone dispensing, drawing on national retail pharmacy data from 2012 through 2018, captured both halves of this story in the same dataset. The good half: dispensing rose substantially across those six years, including a 106 percent jump in the single year between 2017 and 2018 alone, a period that overlaps almost exactly with the wave of states adopting standing orders. The half that qualifies it: even at that 2018 peak, the national dispensing rate amounted to just one naloxone prescription for every 69 high-dose opioid prescriptions written — meaning the population statistically most likely to need a rescue dose on hand was, by CDC's own benchmark, still overwhelmingly not being reached. And the geographic breakdown inside that same analysis found a 25-fold variation in dispensing rates across U.S. counties, with the lowest rates concentrated in the most rural areas — precisely the places where the nearest emergency responder is often furthest away, and where a bystander's own naloxone dose is doing the most work an ambulance can't yet do.
The law now covers nearly the whole country. What varies is whether the pharmacy on the corner ever signed up to use it.
What 351 Massachusetts Towns Show, Town by Town
A national dispensing rate can show that access improved somewhere; it can't show what that access actually did to the death count. For that, researchers from Boston University School of Public Health, Boston Medical Center, Brandeis University, and West Virginia University built a study designed around the fact that Massachusetts's roughly 351 municipalities adopted the state's standing order at different times, letting the towns that hadn't adopted it yet function as a natural comparison group for the ones that had. Published in JAMA Network Open in 2024, the analysis covered 24 quarters — January 2013 through December 2018 — across all 351 towns, using pharmacy participation data covering roughly 70 percent of the state's retail pharmacies. The adoption curve is its own small history of the policy taking hold: zero municipalities had a pharmacy using the standing order in 2013; 17 did by the end of 2014, the first year it existed as a voluntary option; 140 by 2015; 196 by 2016; 209 by 2017; and 214 — nearly 61 percent of all Massachusetts municipalities — by the time the order became mandatory at the end of 2017 pushed the remaining holdouts in.
The Effect That Wasn't There Immediately — and Then Was
The study's central finding runs against the intuitive version of this story, in a way that makes it more credible rather than less. Towns weren't shown to see an immediate drop in overdose deaths the moment their pharmacies opted in — the adjusted rate ratio for that immediate change came to 1.09, with a confidence interval crossing 1.0 and not reaching statistical significance. What showed up instead was a slope: over the following quarters and years, towns using the standing order diverged gradually and significantly from towns that didn't, at an annualized adjusted rate ratio of 0.84 — a 16 percent relative decline in opioid fatality rate per year, compounding, that held up across five separate sensitivity analyses researchers ran to stress-test the result. That delay is not a flaw in the finding; it's a description of how a legal option becomes an actual behavior. A pharmacy having the right to dispense naloxone without a prescription doesn't automatically mean the community knows to ask for it, that pharmacists are comfortable offering it unprompted, or that the people most at risk have started treating the pharmacy counter as a place they can go. The researchers noted the towns that eventually adopted the standing order had a meaningfully higher baseline opioid fatality rate in 2013 — 3.51 per 100,000, versus 1.03 per 100,000 in towns that never adopted it — a reminder that adoption itself wasn't random; towns facing a worse crisis were more likely to take up the option, which is exactly the population in which a 16-percent-a-year divergence matters most.
The Gap the Signature Alone Can't Close
Put the national and Massachusetts findings next to each other and a specific, actionable shape emerges. The legal barrier — a doctor's individual prescription standing between an at-risk person and a reversal drug — has been dismantled in nearly every U.S. jurisdiction; that fight is functionally over. What's left is an implementation gap the law itself doesn't close automatically: the 25-fold county variation CDC found sitting on top of a legal landscape that, on paper, treats every county the same; the multi-year lag before Massachusetts's towns saw their fatality rates actually diverge; and a national dispensing rate that, even after a 106 percent single-year surge, still lands at one naloxone script for every 69 high-dose opioid prescriptions. More than 80,000 Americans died of opioid-related overdose in 2023 alone. Every one of the mechanisms in this piece — the standing order's spread, the slow build of the Massachusetts effect, the persistence of the rural dispensing gap — describes the same underlying fact from a different angle: the difference between a law existing and a law reaching the specific pharmacy counter nearest to the specific person who needed it that night.
And Then You're Dead
A standing order doesn't save anyone by existing on a state health department's letterhead. It saves someone only at the moment a specific pharmacist, in a specific town, hands a specific box across a specific counter to someone who wouldn't otherwise have had it — and the data says that moment took Massachusetts's communities years to fully build into a habit, not months, and still hasn't reached rural America at anything close to the rate it's reached everywhere else. The overdoses the law prevented don't show up anywhere with a name attached. The ones it didn't reach in time still do.
That's it. That's the whole thing.
Sources
- Retail pharmacy naloxone dispensing rising substantially from 2012 to 2018, including a 106 percent increase from 2017 to 2018 alone, with the national rate reaching one naloxone prescription dispensed for every 69 high-dose opioid prescriptions, and a 25-fold county-level variation concentrated in rural areas — CDC Vital Signs, "Pharmacy-Based Naloxone Dispensing," MMWR Vol. 68, August 2019
- Arizona's statewide naloxone standing order taking effect August 6, 2016, and Massachusetts making pharmacy standing-order participation mandatory by the end of 2017 after a voluntary period beginning in 2014 — state naloxone access law documentation, cross-referenced in JAMA Network Open 2024 study methodology
- 29 states with statewide naloxone standing orders as of June 2019, growing to 33 jurisdictions with jurisdiction-wide standing orders by January 2023, out of all 50 states and Washington, D.C. with some form of naloxone access law — Network for Public Health Law, 50-State Survey of Naloxone Access Laws
- A JAMA Network Open interrupted-time-series analysis of all 351 Massachusetts municipalities across 24 quarters (2013–2018), covering roughly 70 percent of the state's retail pharmacies, finding no significant immediate change in opioid fatality rates at standing-order implementation (adjusted rate ratio 1.09) but a significant annualized 16 percent relative decline thereafter (adjusted rate ratio 0.84), confirmed across five sensitivity analyses, alongside town-by-town standing-order adoption counts (0 in 2013, rising to 214 of 351 towns by 2018) and baseline 2013 opioid fatality rates (3.51 per 100,000 in eventually-adopting towns versus 1.03 per 100,000 in never-adopting towns) — "Pharmacy Naloxone Standing Order and Community Opioid Fatality Rates Over Time," JAMA Network Open, 2024
- More than 80,000 opioid-related overdose deaths occurring in the United States in 2023 — cited in Boston University School of Public Health coverage of the JAMA Network Open study
- Photo: "Opiod Rescue Kit 1.jpg," Intropin (Mark Oniffrey), CC BY-SA 4.0, via Wikimedia Commons
Comments
Loading…